Shots:
AbCellera to receive research fees and will be eligible to receive clinical and commercial milestones along with royalties on net sales of products. The companies collaborated to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company
Under the terms of collaboration, Atlas’ portfolio company to get rights to develop and commercialize therapeutic Abs
The collaboration will use AbCellera’s technology and Atlas’ track record of creating an innovative biotechnology company to advance new drug programs more quickly and cost-effectively
Ref: AbCellera | Image: AbCellera
